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Abstract
Background: The polycystic ovary syndrome (PCOS), a common endocrine disorder in women of child-bearing
age, mainly characterised by chronic anovulation and hyperandrogenism, is often associated with insulin resistance
(IR) and obesity. Its etiology and the role of IR and obesity in PCOS are not fully understood. We examined the
influence of validated genetic variants conferring susceptibility to obesity and/or type 2 diabetes mellitus (T2DM)
on metabolic and PCOS-specific traits in patients with PCOS.
Methods: We conducted an association study in 386 patients with PCOS (defined by the Rotterdam-criteria) using
single nucleotide polymorphisms (SNPs) in or in proximity to the fat mass and obesity associated gene (FTO),
insulin-induced gene-2 (INSIG2), transcription factor 7-like 2 gene (TCF7L2) and melanocortin 4 receptor gene
(MC4R). To compare the effect of FTO obesity risk alleles on BMI in patients with PCOS to unselected females of
the same age range we genotyped 1,971 females from the population-based KORA-S4 study (Kooperative
Gesundheitsforschung im Raum Augsburg, Survey 4).
Results: The FTO risk allele was associated with IR traits and measures of increased body weight. In addition, the
TCF7L2 SNP was associated with body weight traits. For the SNPs in the vicinity of INSIG2 and MC4R and for the
other examined phenotypes there was no evidence for an association. In PCOS the observed per risk allele effect
of FTO intron 1 SNP rs9939609 on BMI was +1.56 kg/m
2, whereas it was +0.46 kg/m
2 in females of the same age
range from the general population as shown previously.
Conclusion: The stronger effect on body weight of the FTO SNP in PCOS might well have implications for the
etiology of the disease.
Background
The polycystic ovary syndrome (PCOS) is a common
endocrinopathy affecting about 6% of women of child-
bearing age [1]. It is classically characterised by chronic
anovulation, hyperandrogenism and polycystic ovarian
morphology on ultrasonography [2]. In addition, a close
relationship exists between obesity, insulin resistance
(IR) and PCOS [3,4]. Despite a growing body of
evidence demonstrating a substantial heritability of
PCOS and the intrinsic impact of IR on the develop-
ment of PCOS, its etiology and underlying pathophysiol-
ogy still remains elusive.
To date, multiple genetic studies in PCOS have been
performed examining genes coding for enzymes of ster-
oid biosynthesis like CYP11, CYP17, CYP19, androgen
receptor, insulin, insulin receptor and enzymes in the
post-receptor signal cascade of insulin. However, a var-
iant contributing substantially to the development of the
PCOS phenotype was not detected [5-8]. Genome-wide
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discovery unbiased with regard to the presumed function
of causal variants. Up to one million single nucleotide
polymorphisms (SNP) that are distributed evenly across
the whole genome are commonly used for this approach.
In the field of human body weight regulation these stu-
dies already had a major impact on the identification of
relevant polygenes. For instance, common variants in the
fat mass and obesity associated gene (FTO) predispose to
an elevated body mass index (BMI) with an increase of
0.36 kg/m
2 BMI units per risk allele. Homozygous risk
allele carriers weighed about three kilograms more and
had 1.67-fold higher odds for obesity compared to adults
not inheriting the risk allele [9]. This robust association
was also detectable in the first GWAS for early onset
extreme obesity [10]. With regard to insulin sensitivity, a
recent British study in healthy adults indicated an asso-
ciation between polymorphisms of the FTO gene and a
decrease in insulin sensitivity, which was presumably
BMI mediated [11]. Barber et al. additionally demon-
strated an association between PCOS status and FTO
obesity risk SNPs in a case-control study [12]. Using a
similar approach, Attaoua et al. discussed the potential
role of FTO variants for the glucose intolerance compo-
nent of the metabolic syndrome in patients with PCOS
[13]. Association with increased risk of obesity has also
been demonstrated for SNP rs7566605 located ~10 kb
upstream of the insulin-induced gene-2 (INSIG2), which
was detected in the first population-based GWAS for
body weight [14]. Results concerning the influence of this
SNP on obesity risk are conflicting, as not all studies
detected the association with obesity [15-18]. However,
in a meta-analysis of case-control and family-based
approaches comprising about 17,000 individuals a mar-
ginal effect of rs7566605 on obesity was still present [19].
Recently, Reinehr et al. showed a lower success rate of a
lifestyle intervention for obese children homozygous for
the risk allele C [20]. A solidly validated gene for type
two diabetes mellitus (T2DM) is the transcription factor
7-like 2 gene (TCF7L2). Identified via a conventional gen-
ome wide linkage scan for T2DM and subsequent fine
mapping [21], it had convincingly been confirmed in
numerous studies including GWAS [22-24]. The gene
codes for a stimulating regulator of proglucagon gene
expression [25]. The proglucagon gene is post-transla-
tionally processed to produce GLP-1, a stimulator of
insulin secretion and biosynthesis and it is an inhibitor of
glucagon release [26]. GWAS reported association of a
SNP in TCF7L2 with T2DM and IR in Caucasians
[21,27,28] but a negative association to body weight
[21,28-30]. In PCOS patients, using a sample size and
design similar to their FTO study [12], a case-control
comparison did not provide evidence for an association
of TCF7L2 variants with disease status [31]. A further
(negative) correlation to weight status was robustly found
for a non-synonymous polymorphism Val103Ile in the
melanocortin-4 receptor gene (MC4R) [32-34]. Interest-
ingly, another genetic locus in the vicinity of the MC4R
was recently also detected by a large-scaled GWAS [35].
The respective SNP was associated with obesity; it is
located 188 downstream of the MC4R; its effect is pre-
sumably exerted by an influence on the expression of the
gene. Additionally, another SNP near the previously
described one, was shown to be associated with waist cir-
cumference and insulin resistance [36].
Given the high prevalence of obesity in PCOS and the
compelling evidence for a substantial genetic back-
ground of both PCOS and obesity, known obesity sus-
ceptibility genes emerge as eligible candidates that
might also be involved in the development of PCOS.
T h e r e f o r ew ee x a m i n e dt h ei n f l u e n c eo ft h ed e s c r i b e d
genetic variants on obesity and other endophenotypes in
patients with PCOS. We considered polymorphisms in
or near FTO, INSIG2, TCF7L2 and MC4R that are all
well supported by large data collections of GWAS or
meta-analyses for our analyses in patients with PCOS.
Methods
Patient Recruitment
The study was approved by the Ethics Committees of
the University of Essen and Munich. All subjects gave
written informed consent. The study was carried out
according to the Declaration of Helsinki.
Consecutive, currently untreated patients with PCOS
(n = 386) were recruited between 2/2001 and 1/2007 at
the outpatient clinic of the Department of Endocrinol-
ogy and Division of Laboratory Research, University of
Duisburg-Essen, Germany.S o m ep a t i e n t sw e r ea l s o
attracted by the PCOS homepage of the clinic http://
www.pco-syndrom.de. PCOS was defined according to
the 2003 Rotterdam criteria, so diagnosis of PCOS was
established, if two of the three criteria chronic anovula-
tion, clinical and/or biochemical hyperandrogenism and
polycystic ovaries (PCO) were fulfilled and other pitui-
tary, adrenal or ovarian diseases could be excluded [2].
Clinical Characterization of Patients
Participants were carefully characterized with regard to
medical history, clinical and socio-demographic variables
using questionnaires, interview, and physical examina-
tions, as previously described in detail [37]. Free andro-
gen index (FAI) was calculated as total testosterone
[nmol/l] × 100/SHBG [nmol/l]. Bioavailable testosterone
concentration was calculated based on measured testos-
terone, SHBG and albumin levels [38]. Variables of IR
and b-cell function were evaluated using a 3-h oral glu-
cose tolerance test. After an overnight fast of 12 h
patients ingested 75 g glucose and had their glucose and
insulin levels determined at baseline and at 30, 60, 90,
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model assessment (HOMA) model [39] and hyperinsuli-
nemia by calculating the area under the curve of insulin
response (AUCI).
Females from the population-based sample (KORA-S4)
KORA (Kooperative Gesundheitsforschung im Raum
Augsburg, Survey 4; ‘Cooperative Health Research in the
Region of Augsburg’) is an epidemiological study group
including 4,261 German adults representative of the
population within the age range of 25-74 years in the
city and region of Augsburg (Bavaria, Germany); pro-
bands were recruited between 1999-2001 [40]. FTO
(rs9939609) genotypes as well as phenotype data were
available for 1,971 females (mean BMI 26.96 ± 5.28 kg/
m
2, mean age 48.85 ± 13.69 years).
Biochemical Analyses
Automated chemiluminescence immunoassay systems
were used for the determination of LH, FSH, TSH, tes-
tosterone, estradiol, cortisol, free thyroxine, prolactin,
blood glucose (ADVIA Centaur, Siemens, Germany),
ACTH, dehydroepiandrosterone sulfate, androstene-
dione, sex hormone-binding globulin, insulin and insu-
lin-like growth factor (IMMULITE 2000, Siemens,
Germany). Measurement of blood glucose was per-
formed by photometric determination (ADVIA 2400,
Siemens, Germany). Intraassay variation was < 5% and
interassay variation was < 8% for all measured variables.
17-hydroxyprogesterone was measured by the BIO-
SOURCE 17-alpha-OH-RIA-CT kit (Biosource Interna-
tional, California, USA) (analytical sensitivity 0.02 ng/
ml) provided by IBL Hamburg (IBL, Gesellschaft für
Immunchemie und Immunbiologie, Hamburg, Ger-
many). The intra- and interassay coefficients of variation
were 5.6 and 7.2% respectively. Except for amenorrhoic
women, all laboratory variables were determined in the
early follicular phase of the menstrual cycle.
Genotyping
Genomic DNA was isolated from EDTA-anticoagulated
blood using standard procedures. Genotyping of FTO
SNP rs9939609 was performed by matrix-assisted laser
desorption ionization-time of flight mass spectrometry
(MALDI-TOF MS) analysis of allele-dependent primer
extension products as described elsewhere [41]. For
MC4R Val103Ile (rs2229616), DNA samples were geno-
typed as described previously. MC4R SNPs rs17782313
and rs12970134 were genotyped using TaqMan® assays
(Applied Biosystems, Foster City, CA, USA). All Taq-
Man® probes and primers were purchased from Applied
Biosystems (assays on demand; http://www.appliedbio-
systems.com). For the TCF7L2 rs79031746, genotyping
was performed by allele-specific PCR reactions (tetra-
ARMS PCR; primers were as follows: (forward inner
primer (C allele): 5’-TAGAGAGCTAAGCACTTTTTA-
GAGAC-3’; reverse inner primer (T allele): 5’-
CTCATACGGCAATTAAATTATAGAA-3’;f o r w a r d
outer primer: 5’-AATTTTTTCACATGTGAAGACA-
TAC-3’; reverse outer primer: 5’-AAGAGATGAAATG-
TAGCAGTGAAG-3’. The C allele is detected by a 202
bp amplicon and the T allele by a 272 bp amplicon.
The product size of two outer primers is 424 bp.
Genotyping of INSIG2 SNP rs7566605 was carried out
by PCR-RFLP with Bsp143I (digests the C-allele; pri-
mers: 5’-TGAAGTTGATCTAATGTTCTCTCTCC-3’
and 5’-AAACCAAGGGAATCGAGAGC-3’). PCR pro-
ducts were run on ethidium bromide-stained 2.5% agar-
ose gels. Positive controls for the variant alleles and a
negative control (water) were run on each gel. To vali-
date the genotypes, allele determinations were rated
independently by at least two experienced individuals.
Discrepancies were resolved unambiguously either by
reaching consensus or by retyping. Missings were
retyped.
Statistical Analyses
All genotype distributions were tested for deviations
from Hardy Weinberg equilibrium (HWE) using the
PLINK software (Version 1.06 [42]) and no evidence for
such deviations was detected (all p >> 0.4). All endophe-
notypes were analysed by either linear or logistic regres-
sion analyses using age in years as a covariate. Each
SNP was analyzed under an (log-) additive genetic
model, except for MC4R (rs2229616), where a dominant
mode of inheritance was assumed. Nominal two-sided
p-values, genetic effect sizes estimates and 95% confi-
dence intervals (CI) for the estimates were derived. To
address, the problem of testing multiple hypotheses, we
also derived multiplicity-adjusted p-values for our stron-
gest association signals (see Table three) using a method
of described in [43]. As secondary analyses, robust linear
regressions were used for the comparison of the PCOS
patients with the population-based females and for an
exploration of joint or interaction effects of FTO and
TCF7L2 SNPs; model assumptions were checked
graphically.
Power calculations were done with the software
QUANTO (Version 1.2.3, http://hydra.usc.edu/gxe). 386
PCOS patients were estimated to yield a power > 0.80
to detect a standardized additive genetic effect size of
0.5 (a = 0.05; two-sided) assuming a minor allele fre-
quency (MAF) of 5% and a standard normally distribu-
ted phenotype. For larger MAFs like 46.2%, smaller
effect sizes of 0.2 will be detectable with a similar
power. For comparison, standardized effect sizes like 0.1
have for example been reported for markers in FTO or
TCF7L2 in unselected or control individuals for quanti-
tative traits [9,44]. A standardized effect size of e.g. 0.1
in the additive genetic model implies that the distribu-
tions for the three genotypes are shifted by 1/10 of as
standard deviation for the respective quantitative trait.
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(1.6%, Table 1), the study was well powered to detect
strong to moderate genetic effects which might be pre-
sent in our highly selected sample of PCOS patients.
Results
The clinical and phenotypical characteristics of the
investigated patients with PCOS as well as the estimated
minor allele frequencies (MAFs) are given in Table 1.
Table 1 also includes subgroup distributions according
to the Rotterdam criteria (hyperandrogenism (HA),
oligo-anovulation (OA) and polycystic ovaries (PCO)) as
metabolic differences between theses subgroups have
been described [45-48].
Exploration of associations between genotypes and
metabolic/obesity related variables in patients with
PCOS revealed some evidence for an association of var-
iants in FTO and TCF7L2, whereas no indication of
association was observable for SNPs in INSIG2 and
MC4R (see Table 2). We estimated that each risk allele
of the polymorphism rs9939609 of FTO increased the
body weight by ~4.6 kg, whereas the BMI was increased
by ~1.6 kg/m
2 and the waist circumference increased by
~3.5 cm. Of note, the effect size of rs9939609 on BMI
in PCOS was larger than in unselected females from the
general population in the same age range (see Figure 1).
For the TCF7L2 polymorphism rs7903146 the per risk
allele effect was ~4.2 kg body weight, ~1.4 kg/m
2 BMI
and ~3.4 cm waist circumference, respectively (for
details see Table 2). There was no evidence for a poten-
tially strong interaction or a correlation between the
FTO (adjusted effect 1.35 kg/m
2 in robust linear regres-
sion) and the TCF7L2 locus (adjusted effect 1.45 kg/m
2).
Moreover, FTO variant rs9939609 was associated with
variables of insulin resistance (see Table 3). As an exam-
ple, the estimated per risk allele effect was 3.25 mU/l for
fasting insulin, which changed to 1.88 mU/l (95%CI 0.22
mU/l; 3.54 mU/l, p-value = 0.03), if BMI was added as a
covariate to the regression model. Thus, even after cor-
recting for BMI, a genetic effect of rs9939609 on fasting
insulin levels was observed. By contrast, there was no
evidence for an association of SNPs in INSIG2, TCF7L2
and MC4R with variables of insulin resistance (for
details see Table 3).
Finally, we investigated the relationship between the
variants and PCOS specific characteristics (for details see
Tables 4 and 5). There was no association to chronic
anovulation, hirsutism, acne, alopecia or androgen levels
for any of the variants. Interestingly, we observed that the
obesity risk allele A of the FTO variant rs9939609 was
less frequently observed in patients with polycystic ovar-
ian morphology (PCO) compared to PCOS patients with-
out PCO (OR = 0.57, 95%, CI 0.36;0.88, p-value = 0.01)
and even after correction for BMI this relationship was
still present (OR = 0.60, 95%CI 0.37;0.93, p-value = 0.02).
Discussion
The influence of FTO intron 1 variation on body weight
r e l a t e dp h e n o t y p e si np a t i e n t sw i t hP C O Si su n d e r -
scored. In population-based GWAS the estimated per
risk allele effect ranged between 0.36 kg/m
2 [9] and 0.66
kg/m
2 [49] for statistical models with a slightly different
set of covariates. In our PCOS sample, we estimated an
average effect of the FTO risk allele of 1.56 kg/m
2 (95%
CI 0.34 kg/m
2;2 . 7 8k g / m
2) including age as a quantita-
tive covariate. Thus, the impact of the FTO variants on
B M Ii sl a r g e ri nP C O Sp a t i e n t st h a ni nt h eg e n e r a l
population with an average effect of the FTO risk allele
of 0.46 kg/m
2 (95%CI 0.17 kg/m
2;0 . 7 5k g / m
2)a ss h o w n
in Figure 1. Of note, our finding is surprisingly similar
Table 1 Characteristics of the investigated samples of the
patients with PCOS (means and standard deviations or
percent).
variables 386 patients with PCOS
age [years] 28.0 ± 6.5
body weight [kg] 88.3 ± 25.8
BMI [kg/m
2] 31.4 ± 8.7
waist [cm] 98.8 ± 62.4
eumenorrhea [%] 8.7
oligomenorrhea [%] 65.7
amenorrhea [%] 25.5
hirsutism-Score [F/G] 8.9 ± 6.6
hirsutism [%] 54.0
acne [%] 47.8
alopecia [%] 27.3
PCO [%] 82.8
HA + OA [%] 92.3
HA + OA with PCO [%] 57.5
HA + OA without PCO [%] 12.2
HA + OA, PCO unknown [%] 30.3
HA + PCO [%] 5.2
OA + PCO [%] 2.5
testosterone [nmol/l] 2.8 ± 2.8
FAI 20.3 ± 83.9
bioavailable testosterone [ng/ml] 0.4 ± 0.8
HOMA-IR [μmol/lxmmol/l
2] 3.7 ± 3.3
AUCI [mUxh/l] 262.6 ± 184.1
FTO (rs9939609; MAF A allele) 46.2
INSIG2 (rs7566605; MAF C allele) 33.8
TCF7L2 (rs7903146; MAF T allele) 28.4
MC4R (rs2229616; MAF T allele) 1.6
MC4R (rs17782313; MAF C allele) 29.0
MC4R (rs12970134; MAF A allele) 31.7
BMI = body mass index; F/G = hirsutism-score by Ferriman/Gallwey; FAI = free
androgen index; PCO = polycystic ovary; HA = hyperandrogenism; OA =
oligo-/amenorrhea; HOMA-IR = homeostasis model assessment for insulin
resistance; AUCI = area under the curve of insulin response; MAF = minor
allele frequency
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per risk allele effect of 1.1 kg/m
2 (95%CI -0.9 kg/m
2;3 . 2
kg/m
2) in their PCOS cases and only 0.5 kg/m
2 (95%CI
-0.1 kg/m
2;1 . 3k g / m
2) in their controls [12]. Moreover,
this study is, to our knowledge, the first to describe a
correlation between FTO rs9939609 and insulin resis-
tance or hyperinsulinemia in PCOS patients reflected in
fasting insulin, HOMA-IR as well as in AUCI levels
After strictly controlling for the multiple statistical tests
performed here (multiple phenotypes and multiple
SNPs) the adjusted p-value for FTO rs9939609 and fast-
ing insulin was 0.062 and the related effect, though
weaker, was still present even after statistically correct-
ing for BMI. Other study groups could not demonstrate
an association between FTO and IR in obese and T2DM
patients, respectively [51,52]. In PCOS, FTO variation
seems to be a key marker for IR, either directly i.e. to
some degree independent of BMI/obesity or secondary
due to its impact on body weight which in turn has an
impact on glucose intolerance and diabetes. Barber et al.
at first demonstrated an association between FTO and
PCOS status and hypothesized a mediation of this asso-
ciation by adiposity. However, in this British sample, no
IR data were available. In a French sample FTO was
associated with both glucose intolerance and metabolic
syndrome [13] without finding an association to IR. The
greater effect on BMI and association to IR in PCOS
possibly reflects a pathogenetic function of the FTO
gene in the development of PCOS. This study and the
data from Barber et al. demonstrated, that the FTO gene
does not influence any of the PCOS defining traits
neither directly nor indirectly via an effect on obesity or
IR. In this German cohort, it is even less frequently
associated with PCO. In case of a pathogenetic role of
FTO in PCOS, it seems to be limited to determine only
the metabolic phenotype.
As second strongest signal, we found association
between the T2DM susceptibility gene TCF7L2 risk
allele and obesity related traits in patients with PCOS.
The TCF7L2 obesity association was stochastically inde-
pendent of the FTO association if assessed in a multiple
regression analysis. While some did not find an influ-
ence on body weight [29,30,53-56], others have reported
analogous associations of TCF7L2 and obesity related
traits [28,43,57]. Despite possible effects related to dif-
ferences in ascertainment schemes, multiple explana-
tions for this conflicting findings are possible [57]. One
possible explanation by Cauchi and collegues [43] is that
the risk for T2DM related to TCF7L2 seems to be
modulated by the obesity status of an individual with
stronger effects in the obese. It is possible that our
study picked-up this BMI-related effect of TCF7L2.A s
we observed no evidence for an association of TCF7L2
with IR or other PCOS specific symptoms, common
Figure 1 Relationship between the FTO SNP rs9939609, BMI and age in females for the general population and in patients with PCOS.
Each dot represents one observation; the lines are derived from a robust linear regression on the complete data set of females with BMI as
outcome and age (linear), group, genotype in the logadditive model and the interaction group x genotype as predictors.
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ceptibility through impairment of insulin secretion
rather than IR [56,58]. Interestingly, this observation is
consistent with the PCOS data of Barber et al. [12] who
failed to detect association of TCF7L2 variation but who
do not report on the genotype dependent BMI-
distribution.
Finally, our data on rs7566605 located ~10 kb
upstream of INSIG2 and on markers in proximity to
MC4R provided no evidence for an involvement in the
development of PCOS or related endophenotypes.
Conclusion
In summary, we explored (mainly) GWAS-derived can-
didate gene markers for obesity and T2DM in patients
with PCOS. We show that the impact of INSIG2,
TCF7L2 and MC4R SNPs on multiple endophenotypes
m i g h te i t h e rb er a t h e rw e a ko rn o tp r e s e n ta ta l l .F o r
genetic variation in intron 1 of FTO we provide evi-
dence for associations to metabolic aspects of PCOS
with some emphasis on IR. Interestingly, the estimated
effect on obesity seems to be larger than the effect
derived from population-based samples. This stronger
Table 2 Association analysis for the relationship between validated SNPs in the explored candidate genes and
quantitative metabolic/obesity related variables in PCOS with genetic effect sizes estimates derived for an additive
genetic (MC4R rs2229616 dominant genetic model) for the minor allele (see also Table 1).
body weight [kg] BMI [kg/m
2] waist [cm]
gene (SNP) minor allele b 95% CI p b 95% CI p b 95% CI p
FTO (rs9939609) A 4.60 (0.97;8.22) 0.01 1.56 (0.34;2.78) 0.01 3.49 (0.62;6.37) 0.02
INSIG2 (rs7566605) C -1.38 (-5.23;2.48) 0.48 -0.35 (-1.66;0.95) 0.59 -1.89 (-4.92;1.15) 0.22
TCF7L2 (rs7903146) T -4.18 (-8.20;-0.15) 0.04 -1.35 (-2.71;0.01) 0.05 -3.43 (-6.63;-0,24) 0.04
MC4R (rs2229616) T -2.12 (-16.88;12.63) 0.78 -0.91 (-5.88;4.06) 0.72 1.14 (-10.01;12.29) 0.84
MC4R (rs17782313) C 0.33 (-3.75;4.42) 0.87 -0.01 (-1.36;1.39) 0.98 0.54 (-2.73;3.81) 0.75
MC4R (rs12970134) A 0.20 (-3.74;4.14) 0.92 -0.12 (-1.45;1.21) 0.86 0.52 (-2,64;3.69) 0.75
SNP = single nucleotide polymorphism; BMI = body mass index
Table 3 Association analysis for the relationship between validated SNPs in the explored candidate genes and
quantitative variables of insulin resistance in PCOS with genetic effect sizes estimates derived for an additive genetic
model (MC4R rs2229616 dominant genetic model) for the minor allele (see also Table 1).
fasting insulin [mU/l] HOMA-IR [μmol/lxmmol/l
2] AUCI [mUxh/l]
gene (SNP) minor allele b 95% CI p b 95% CI p b 95% CI p
FTO (rs9939609) A 3.25 (1.32;5.18) 0.001* 0.76 (0.29;1.23) 0.002* 35.92 (9.63;62.21) 0.01
INSIG2 (rs7566605) C 0.85 (-1.21;2.90) 0.42 0.33 (-0.18;0.83) 0.21 12.92 (-14.83;40.68) 0.36
TCF7L2 (rs7903146) T -0.23 (-2.40;1.93) 0.83 -0.13 (-0.66;0.40) 0.63 -5.18 (-34.27;23.91) 0.73
MC4R (rs2229616) T 3.20 (-4.67;11.07) 0.43 -0.46 (-2.45;1.53) 0.65 -8.25 (-117.9;101.4) 0.88
MC4R (rs17782313) C 1.10 (-1.08;3.28) 0.32 0.17 (-0.36;0.70) 0.54 4.52 (-25.02;34.06) 0.76
MC4R (rs12970134) A 1.07 (-1.03;3.18) 0.32 0.20 (-0.31;0.71) 0.45 1.23 (-27.21;29.68) 0.93
SNP = single nucleotide polymorphism; HOMA-IR = homeostasis model assessment for insulin resistance; AUCI = area under the curve of insulin response
*both associations would have been “significant” at the alpha = 0.10 level if correction for multiple testing would have been applied resulting in adjusted p-
values of 0.062 for rs9939609 and fasting insulin and 0.099 for rs9939609 and HOMA-IR
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the disease requiring focussed functional studies.
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Table 4 Association analysis for the relationship between validated SNPs in the explored candidate genes and PCOS
symptoms (present/absent) with genetic effect sizes estimates derived for an log-additive genetic model (MC4R
rs2229616 dominant genetic model) for the minor allele (see also Table 1).
chronic anovulation hirsutism-score [F/G] > 7
hirsutism-score [F/G]
alopecia acne PCO
gene (SNP)
minor allele
OR 95% CI p OR b 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
FTO
(rs9939609) A
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0.90 (0.65;1.24) 0.50 0.97 (0.73;1.30) 0.85 0.57 (0.36;0.88) 0.01
INSIG2
(rs7566605) C
1.02 (0.54;1.90) 0.96 1.03
-0.08
(0.76;1.38)
(1.06;0.90)
0.87
0.87
1.17 (0.83;1.64) 0.37 1.00 (0.74;1.35) 0.99 1.02 (0.65;1.60) 0.93
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(rs7903146) T
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0.09
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(0.95;1.12)
0.44
0.87
0.75 (0.51;1.08) 0.12 0.84 (0.61;1.15) 0.28 0.77 (0.48;1.21) 0.25
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(rs2229616) T
- - - 1.73
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MC4R
(rs17782313) C
1.01 (0.52;1.95) 0.98 0.85
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(0.88;1.21)
0.33
0.76
1.01 (0.70;1.44) 0.98 1.04 (0.76;1.43) 0.81 0.95 (0.59;1.52) 0.82
MC4R
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0.83
0.43
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SNP = single nucleotide polymorphism; F/G = hirsutism-score by Ferriman/Gallwey
Note that the hirsutism-score was also evaluated quantitatively similar to the other quantitative measures (in italics).
Table 5 Association analysis for the relationship between validated SNPs in the explored candidate genes and
quantitative variables of hyperandrogenemia in PCOS with genetic effect sizes estimates derived for a log-additive
genetic model (MC4R rs2229616 dominant genetic model) for the minor allele (see also Table 1).
testosterone [nmol/l] FAI bioavailable testosterone [ng/ml]
gene (SNP) minor allele b 95% CI p b 95% CI p b 95% CI p
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MC4R (rs12970134) A 0.15 (-0.29;0.58) 0.51 7.26 (-5.97;20.49) 0.28 0.07 (-0.06;0.19) 0.30
SNP = single nucleotide polymorphism; FAI = free androgen index
Tan et al. BMC Medical Genetics 2010, 11:12
http://www.biomedcentral.com/1471-2350/11/12
Page 7 of 9Wuppertal, Germany.
5Department of Child and Adolescent Psychiatry,
University of Duisburg-Essen, Essen, Germany.
6Institute of Epidemiology,
GSF - National Research Center for Environment and Health, Munich,
Germany.
7Department of Gynecology and Obstetrics, University of
Duisburg-Essen, Essen, Germany.
Authors’ contributions
ST contributed substantially to conception and design of the study,
acquisition of data, analysis and interpretation of data and drafted the
manuscript. AS contributed substantially to conception and design of the
study, analysis of data, performed the statistical analysis and drafted the
manuscript. OEJ, SH, HL, TD, RK and KM contributed to acquisition of data
and revised the manuscript critically for important intellectual content. SS
and CIGV carried out the molecular genetic studies for polymorphisms of
TCF7L2, INSIG2 and MC4R and revised the manuscript critically for important
intellectual content. HG and TI contributed to acquisition of data, carried out
the molecular genetic studies for polymorphisms of FTO and revised the
manuscript critically for important intellectual content. JH and AH
contributed substantially to conception and design of the study, analysis
and interpretation of data and were involved in drafting the manuscript and
haves given final approval of the version to be published. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 June 2009
Accepted: 21 January 2010 Published: 21 January 2010
References
1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The
prevalence and features of the polycystic ovary syndrome in an
unselected population. J Clin Endocrinol Metab 2004, 89:2745-2749.
2. Revised 2003 consensus on diagnostic criteria and long-term health
risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
3. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ,
Franks S: Improvement in endocrine and ovarian function during dietary
treatment of obese women with polycystic ovary syndrome. Clin
Endocrinol (Oxf) 1992, 36:105-111.
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral
insulin resistance, independent of obesity, in polycystic ovary syndrome.
Diabetes 1989, 38:1165-1174.
5. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O’Rahilly S, Clayton RN:
Molecular scanning of the insulin receptor gene in women with
polycystic ovarian syndrome. J Clin Endocrinol Metab 1996, 81:1979-1983.
6. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E: Defects in insulin receptor
signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol
Endocrinol Metab 2001, 281:E392-399.
7. Legro RS, Strauss JF: Molecular progress in infertility: polycystic ovary
syndrome. Fertil Steril 2002, 78:569-576.
8. Stewart DR, Dombroski BA, Urbanek M, Ankener W, Ewens KG, Wood JR,
Legro RS, Strauss JF, Dunaif A, Spielman RS: Fine mapping of genetic
susceptibility to polycystic ovary syndrome on chromosome 19p13.2
and tests for regulatory activity. J Clin Endocrinol Metab 2006,
91:4112-4117.
9. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM,
Perry JR, Elliott KS, Lango H, Rayner NW, et al: A common variant in the
FTO gene is associated with body mass index and predisposes to
childhood and adult obesity. Science 2007, 316:889-894.
10. Hinney A, Nguyen TT, Scherag A, Friedel S, Bronner G, Muller TD, Grallert H,
Illig T, Wichmann HE, Rief W, et al: Genome wide association (GWA) study
for early onset extreme obesity supports the role of fat mass and
obesity associated gene (FTO) variants. PLoS ONE 2007, 2:e1361.
11. Pascoe L, Tura A, Patel SK, Ibrahim IM, Ferrannini E, Zeggini E, Weedon MN,
Mari A, Hattersley AT, McCarthy MI, et al: Common variants of the novel
type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with
decreased pancreatic beta-cell function. Diabetes 2007, 56:3101-3104.
12. Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H,
Pouta A, Hartikainen AL, Elliott P, Lindgren CM, et al: Association of
variants in the fat mass and obesity associated (FTO) gene with
polycystic ovary syndrome. Diabetologia 2008, 51:1153-1158.
13. Attaoua R, Ait El Mkadem S, Radian S, Fica S, Hanzu F, Albu A,
Gheorghiu M, Coculescu M, Grigorescu F: FTO gene associates to
metabolic syndrome in women with polycystic ovary syndrome. Biochem
Biophys Res Commun 2008, 373:230-234.
14. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, Wichmann HE,
Meitinger T, Hunter D, Hu FB, et al: A common genetic variant is
associated with adult and childhood obesity. Science 2006, 312:279-283.
15. Kumar J, Sunkishala RR, Karthikeyan G, Sengupta S: The common genetic
variant upstream of INSIG2 gene is not associated with obesity in Indian
population. Clin Genet 2007, 71:415-418.
16. Loos RJ, Barroso I, O’Rahilly S, Wareham NJ: Comment on “A common
genetic variant is associated with adult and childhood obesity”. Science
2007, 315:187.
17. Dina C, Meyre D, Samson C, Tichet J, Marre M, Jouret B, Charles MA,
Balkau B, Froguel P: Comment on “A common genetic variant is
associated with adult and childhood obesity”. Science 2007, 315:187.
18. Rosskopf D, Bornhorst A, Rimmbach C, Schwahn C, Kayser A, Kruger A,
Tessmann G, Geissler I, Kroemer HK, Volzke H: Comment on “A common
genetic variant is associated with adult and childhood obesity”. Science
2007, 315:187.
19. Lyon HN, Emilsson V, Hinney A, Heid IM, Lasky-Su J, Zhu X, Thorleifsson G,
Gunnarsdottir S, Walters GB, Thorsteinsdottir U, et al: The association of a
SNP upstream of INSIG2 with body mass index is reproduced in several
but not all cohorts. PLoS Genet 2007, 3:e61.
20. Reinehr T, Hinney A, Nguyen TT, Hebebrand J: Evidence of an influence of
a polymorphism near the INSIG2 on weight loss during a lifestyle
intervention in obese children and adolescents. Diabetes 2008,
57:623-626.
21. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A,
Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, et al: Variant
of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2
diabetes. Nat Genet 2006, 38:320-323.
22. Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA, Dupuis J:
Genome-wide association with diabetes-related traits in the
Framingham Heart Study. BMC Med Genet 2007, 8(Suppl 1):S16.
23. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P,
Sjogren M, Ling C, Eriksson KF, Lethagen AL, et al: Mechanisms by which
common variants in the TCF7L2 gene increase risk of type 2 diabetes. J
Clin Invest 2007, 117:2155-2163.
24. Palmer ND, Lehtinen AB, Langefeld CD, Campbell JK, Haffner SM, Norris JM,
Bergman RN, Goodarzi MO, Rotter JI, Bowden DW: Association of TCF7L2
gene polymorphisms with reduced acute insulin response in Hispanic
Americans. J Clin Endocrinol Metab 2008, 93:304-309.
25. Yi F, Brubaker PL, Jin T: TCF-4 mediates cell type-specific regulation of
proglucagon gene expression by beta-catenin and glycogen synthase
kinase-3beta. J Biol Chem 2005, 280:1457-1464.
26. Deacon CF: Therapeutic strategies based on glucagon-like peptide 1.
Diabetes 2004, 53:2181-2189.
27. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D,
Belisle A, Hadjadj S, et al: A genome-wide association study identifies
novel risk loci for type 2 diabetes. Nature 2007, 445:881-885.
28. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S,
Adeyemo A, Chen Y, Chen G, Reynisdottir I, et al: Refining the impact of
TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat
Genet 2007, 39:218-225.
29. Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjogren M,
Florez JC, Almgren P, Isomaa B, Orho-Melander M, et al: Common single
nucleotide polymorphisms in TCF7L2 are reproducibly associated with
type 2 diabetes and reduce the insulin response to glucose in
nondiabetic individuals. Diabetes 2006, 55:2890-2895.
30. Cauchi S, Meyre D, Dina C, Choquet H, Samson C, Gallina S, Balkau B,
Charpentier G, Pattou F, Stetsyuk V, et al: Transcription factor TCF7L2
genetic study in the French population: expression in human beta-cells
and adipose tissue and strong association with type 2 diabetes. Diabetes
2006, 55:2903-2908.
31. Barber TM, Bennett AJ, Groves CJ, Sovio U, Ruokonen A, Martikainen H,
Pouta A, Hartikainen AL, Elliott P, Wass JA, et al: Disparate genetic
influences on polycystic ovary syndrome (PCOS) and type 2 diabetes
revealed by a lack of association between common variants within the
TCF7L2 gene and PCOS. Diabetologia 2007, 50:2318-2322.
Tan et al. BMC Medical Genetics 2010, 11:12
http://www.biomedcentral.com/1471-2350/11/12
Page 8 of 932. Geller F, Reichwald K, Dempfle A, Illig T, Vollmert C, Herpertz S, Siffert W,
Platzer M, Hess C, Gudermann T, et al: Melanocortin-4 receptor gene
variant I103 is negatively associated with obesity. Am J Hum Genet 2004,
74:572-581.
33. Heid IM, Vollmert C, Hinney A, Doring A, Geller F, Lowel H, Wichmann HE,
Illig T, Hebebrand J, Kronenberg F: Association of the 103I MC4R allele
with decreased body mass in 7937 participants of two population based
surveys. J Med Genet 2005, 42:e21.
34. Young EH, Wareham NJ, Farooqi S, Hinney A, Hebebrand J, Scherag A,
O’Rahilly S, Barroso I, Sandhu MS: The V103I polymorphism of the MC4R
gene and obesity: population based studies and meta-analysis of 29 563
individuals. Int J Obes (Lond) 2007, 31:1437-1441.
35. Loos RJ, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M,
Freathy RM, Attwood AP, Beckmann JS, et al: Common variants near MC4R
are associated with fat mass, weight and risk of obesity. Nat Genet 2008,
40:768-775.
36. Chambers JC, Elliott P, Zabaneh D, Zhang W, Li Y, Froguel P, Balding D,
Scott J, Kooner JS: Common genetic variation near MC4R is associated
with waist circumference and insulin resistance. Nat Genet 2008,
40:716-718.
37. Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M,
Elsenbruch S, Kimmig R, Mann K, Janssen OE: Metformin improves
polycystic ovary syndrome symptoms irrespective of pre-treatment
insulin resistance. Eur J Endocrinol 2007, 157:669-676.
38. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple
methods for the estimation of free testosterone in serum. J Clin
Endocrinol Metab 1999, 84:3666-3672.
39. Hermans MP, Levy JC, Morris RJ, Turner RC: Comparison of tests of beta-
cell function across a range of glucose tolerance from normal to
diabetes. Diabetes 1999, 48:1779-1786.
40. Holle R, Happich M, Lowel H, Wichmann HE: KORA–a research platform
for population based health research. Gesundheitswesen 2005, 67(Suppl
1):S19-25.
41. Vollmert C, Windl O, Xiang W, Rosenberger A, Zerr I, Wichmann HE,
Bickeboller H, Illig T, Kretzschmar HA: Significant association of a M129V
independent polymorphism in the 5’ UTR of the PRNP gene with
sporadic Creutzfeldt-Jakob disease in a large German case-control study.
J Med Genet 2006, 43:e53.
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum
Genet 2007, 81:559-575.
43. Cauchi S, Nead KT, Choquet H, Horber F, Potoczna N, Balkau B, Marre M,
Charpentier G, Froguel P, Meyre D: The genetic susceptibility to type 2
diabetes may be modulated by obesity status: implications for
association studies. BMC Med Genet 2008, 9:45.
44. Stolerman ES, Manning AK, McAteer JB, Fox CS, Dupuis J, Meigs JB,
Florez JC: TCF7L2 variants are associated with increased proinsulin/
insulin ratios but not obesity traits in the Framingham Heart Study.
Diabetologia 2009, 52:614-620.
45. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA,
Carmina E: Milder forms of atherogenic dyslipidemia in ovulatory versus
anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009,
24:2286-2292.
46. Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD: Endocrine
and metabolic differences among phenotypic expressions of polycystic
ovary syndrome according to the 2003 Rotterdam consensus criteria.
Am J Obstet Gynecol 2008, 198:670.
47. Barber TM, Wass JA, McCarthy MI, Franks S: Metabolic characteristics of
women with polycystic ovaries and oligo-amenorrhoea but normal
androgen levels: implications for the management of polycystic ovary
syndrome. Clin Endocrinol (Oxf) 2007, 66:513-517.
48. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P: Oligoanovulation
with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol
Metab 2006, 91:3922-3927.
49. Scuteri A, Sanna S, Chen WM, Uda M, Albai G, Strait J, Najjar S, Nagaraja R,
Orru M, Usala G, et al: Genome-wide association scan shows genetic
variants in the FTO gene are associated with obesity-related traits. PLoS
Genet 2007, 3:e115.
50. Kowalska I, Malecki MT, Straczkowski M, Skupien J, Karczewska-
Kupczewska M, Nikolajuk A, Szopa M, Adamska A, Wawrusiewicz-
Kurylonek N, Wolczynski S, et al: The FTO gene modifies weight, fat mass
and insulin sensitivity in women with polycystic ovary syndrome, where
its role may be larger than in other phenotypes. Diabetes Metab 2009,
35(4):328-31.
51. Horikoshi M, Hara K, Ito C, Shojima N, Nagai R, Ueki K, Froguel P,
Kadowaki T: Variations in the HHEX gene are associated with increased
risk of type 2 diabetes in the Japanese population. Diabetologia 2007,
50:2461-2466.
52. Wahlen K, Sjolin E, Hoffstedt J: The common rs9939609 gene variant of
the fat mass- and obesity-associated gene FTO is related to fat cell
lipolysis. J Lipid Res 2008, 49:607-611.
53. Marzi C, Huth C, Kolz M, Grallert H, Meisinger C, Wichmann HE,
Rathmann W, Herder C, Illig T: Variants of the transcription factor 7-like 2
gene (TCF7L2) are strongly associated with type 2 diabetes but not with
the metabolic syndrome in the MONICA/KORA surveys. Horm Metab Res
2007, 39:46-52.
54. Melzer D, Murray A, Hurst AJ, Weedon MN, Bandinelli S, Corsi AM,
Ferrucci L, Paolisso G, Guralnik JM, Frayling TM: Effects of the diabetes
linked TCF7L2 polymorphism in a representative older population. BMC
Med 2006, 4:34.
55. Chandak GR, Janipalli CS, Bhaskar S, Kulkarni SR, Mohankrishna P,
Hattersley AT, Frayling TM, Yajnik CS: Common variants in the TCF7L2
gene are strongly associated with type 2 diabetes mellitus in the Indian
population. Diabetologia 2007, 50:63-67.
56. Loos RJ, Franks PW, Francis RW, Barroso I, Gribble FM, Savage DB, Ong KK,
O’Rahilly S, Wareham NJ: TCF7L2 polymorphisms modulate proinsulin
levels and beta-cell function in a British Europid population. Diabetes
2007, 56:1943-1947.
57. Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR,
Knowler WC, Nathan DM, Altshuler D: TCF7L2 polymorphisms and
progression to diabetes in the Diabetes Prevention Program. N Engl J
Med 2006, 355:241-250.
58. Pascoe L, Frayling TM, Weedon MN, Mari A, Tura A, Ferrannini E, Walker M:
Beta cell glucose sensitivity is decreased by 39% in non-diabetic
individuals carrying multiple diabetes-risk alleles compared with those
with no risk alleles. Diabetologia 2008, 51:1989-1992.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2350/11/12/prepub
doi:10.1186/1471-2350-11-12
Cite this article as: Tan et al.: Large effects on body mass index and
insulin resistance of fat mass and obesity associated gene (FTO)
variants in patients with polycystic ovary syndrome (PCOS). BMC Medical
Genetics 2010 11:12.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tan et al. BMC Medical Genetics 2010, 11:12
http://www.biomedcentral.com/1471-2350/11/12
Page 9 of 9